Bosh sahifaSDZ • SWX
add
Sandoz Group AG
Yopilish kursi
48,25 CHF
Kunlik diapazon
47,55 CHF - 48,25 CHF
Yillik diapazon
26,25 CHF - 50,88 CHF
Bozor kapitalizatsiyasi
20,97 mlrd CHF
Oʻrtacha hajm
831,16 ming
Narx/foyda
116,00
Dividend daromadliligi
1,25%
Asosiy maydon
SWX
Bozor yangiliklari
CNBC
20 soat oldin
S&P 500 fights for another record — plus, Eaton signals big data center opportunity
0,048%
1,62%
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 2,63 mlrd | 4,01% |
Joriy xarajat | 904,50 mln | -11,67% |
Sof foyda | 188,50 mln | 151,33% |
Sof foyda marjasi | 7,16 | 141,89% |
Har bir ulushga tushum | — | — |
EBITDA | 415,00 mln | 53,42% |
Amaldagi soliq stavkasi | 25,20% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 1,39 mlrd | 98,15% |
Jami aktivlari | 21,61 mlrd | 11,86% |
Jami passivlari | 12,79 mlrd | 16,79% |
Umumiy kapital | 8,82 mlrd | — |
Tarqatilgan aksiyalar | 432,00 mln | — |
Narxi/balansdagi bahosi | 2,36 | — |
Aktivlardan daromad | 3,48% | — |
Kapitaldan daromad | 5,18% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 188,50 mln | 151,33% |
Operatsiyalardan naqd pul | 261,50 mln | 128,38% |
Sarmoyadan naqd pul | -158,00 mln | 19,80% |
Moliyadan naqd pul | -74,00 mln | 35,09% |
Naqd pulning sof oʻzgarishi | 99,00 mln | 148,53% |
Boʻsh pul | 151,94 mln | 47,69% |
Haqida
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland, with most of global functions operating from Holzkichen in Germany, Prague in Czechia, and Barcelona in Spain. Sandoz is the global leader in generic pharmaceuticals and biosimilars. Wikipedia
Tashkil etilgan
1886
Sayt
Xodimlar soni
20 000
